Get the Stockscreener App
5.465
4.79%
-0.275
Verrica Pharmaceuticals Inc stock is traded at $5.465, with a volume of 50,701.
It is down -4.79% in the last 24 hours and down -24.31% over the past month.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
See More
Previous Close:
$5.74
Open:
$5.78
24h Volume:
50,701
Relative Volume:
1.04
Market Cap:
$51.62M
Revenue:
$5.12M
Net Income/Loss:
$-67.00M
P/E Ratio:
-3.7177
EPS:
-1.47
Net Cash Flow:
$-38.94M
1W Performance:
-8.31%
1M Performance:
-24.31%
6M Performance:
-25.76%
1Y Performance:
-80.41%
1-Day Range:
$5.40
$5.78
1-Week Range:
$5.40
$6.36
52-Week Range:
$3.816
$29.70
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Name
Verrica Pharmaceuticals Inc
Sector
Industry
Phone
484-453-3300
Address
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.465 | 58.14M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-25-23 | Upgrade | Needham | Hold → Buy |
| Mar-22-23 | Initiated | Jefferies | Buy |
| Feb-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-25-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-20 | Initiated | Northland Capital | Outperform |
| Mar-24-20 | Initiated | Needham | Buy |
| Feb-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Verrica Pharmaceuticals Inc Stock (VRCA) Latest News
Published on: 2025-08-21 06:55:08 - newsyoung.net
Bollinger Bands Expand on Verrica Pharmaceuticals Inc. — Volatility AheadMarket Weekly Review & Weekly Setup with High ROI Potential - thegnnews.com
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Declines By 32.3% - Defense World
Verrica Pharmaceuticals Inc.’s volatility index tracking explainedInsider Buying & Expert-Curated Trade Recommendations - Newser
Can Verrica Pharmaceuticals Inc. hit a new high this monthTrade Risk Summary & Weekly High Return Stock Opportunities - Newser
Real time scanner hits for Verrica Pharmaceuticals Inc. explainedQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - Newser
Detecting price anomalies in Verrica Pharmaceuticals Inc. with AIJuly 2025 Highlights & Low Risk Investment Opportunities - Newser
Verrica Pharmaceuticals Streamlines Operations to Enhance YCANTH Access - MSN
Verrica Pharmaceuticals Inc. stock trend outlook and recovery pathWeekly Stock Recap & Weekly High Conviction Trade Ideas - Newser
Is Verrica Pharmaceuticals Inc. showing signs of accumulationQuarterly Trade Review & Free Accurate Trade Setup Notifications - Newser
What earnings revisions data tells us about Verrica Pharmaceuticals Inc.July 2025 Closing Moves & Weekly Setup with ROI Potential - Newser
Verrica Pharmaceuticals Posts Strong Q2 Growth, Advances Basal Cell Carcinoma Program - MSN
Can Verrica Pharmaceuticals Inc. recover in the next quarter2025 Market Sentiment & Daily Market Momentum Tracking - Newser
Leading vs lagging indicators on Verrica Pharmaceuticals Inc. performance2025 Short Interest & Target Return Focused Stock Picks - Newser
Real time social sentiment graph for Verrica Pharmaceuticals Inc.July 2025 Decliners & Low Risk High Reward Ideas - Newser
Verrica Pharmaceuticals Inc. Ranks High in Smart Money TrackerWeekly Trading Summary & Free Safe Capital Growth Stock Tips - beatles.ru
Can machine learning forecast Verrica Pharmaceuticals Inc. recoveryQuarterly Trade Review & Growth Focused Entry Reports - Newser
Analyzing drawdowns of Verrica Pharmaceuticals Inc. with statistical tools - Newser
Sentiment analysis tools applied to Verrica Pharmaceuticals Inc.Market Volume Summary & Real-Time Volume Triggers - Newser
What does recent volatility data suggest for Verrica Pharmaceuticals Inc.Market Risk Analysis & Growth Focused Stock Reports - Newser
Verrica Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - Newser
Is Verrica Pharmaceuticals Inc. trending in predictive chart modelsTake Profit & Verified Swing Trading Watchlist - Newser
Does Verrica Pharmaceuticals Inc. have declining or rising EPSQuarterly Market Review & Scalable Portfolio Growth Ideas - sundaytimes.kr
Why Verrica Pharmaceuticals Inc. stock attracts strong analyst attention2025 Historical Comparison & Reliable Volume Spike Alerts - Newser
Market reaction to Verrica Pharmaceuticals Inc.’s recent newsGlobal Markets & Risk Adjusted Swing Trade Ideas - Newser
Sector ETF Data Correlates with Strength in Verrica Pharmaceuticals Inc.Trade Analysis Report & Growth Oriented Trading Recommendations - sundaytimes.kr
What makes Verrica Pharmaceuticals Inc. stock price move sharply2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
Historical volatility pattern of Verrica Pharmaceuticals Inc. visualized2025 Major Catalysts & Long Hold Capital Preservation Plans - Newser
Verrica Pharmaceuticals shares rise 2.28% after-hours following Q2 2025 earnings call. - AInvest
Verrica Posts Profit in Fiscal Q2 - AOL.com
Verrica Pharmaceuticals stock price target raised to $20 by TD Cowen - Investing.com Canada
Verrica Pharmaceuticals Reaches Nasdaq Compliance, Q2 Revenue at $12.7M - AInvest
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q2 2025 Earnings Call Transcript - Insider Monkey
Verrica Pharmaceuticals: Promising Sales Growth Amid Financial Stability Concerns - TipRanks
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates - MSN
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Sees Revenue Surge in Q2 2025 - TipRanks
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewswire
Verrica Posts Profit in Fiscal Q2 - The Motley Fool
Verrica Pharmaceuticals' Q2 2025: Unpacking Contradictions in Sales Strategies, Seasonality, and Patient Access - AInvest
Verrica Pharmaceuticals (VRCA) Q2 2025 Earnings and Strategic Pipeline Catalysts: A Case for Re-Rating and Investor Re-Entry - AInvest
Earnings call transcript: Verrica Pharmaceuticals Q2 2025 beats EPS forecast By Investing.com - Investing.com Nigeria
Earnings call transcript: Verrica Pharmaceuticals Q2 2025 beats EPS forecast - Investing.com
Verrica Pharmaceuticals Regains Nasdaq Compliance - TipRanks
VERRICA PHARMACEUTICAL Earnings Results: $VRCA Reports Quarterly Earnings - Quiver Quantitative
Verrica Pharmaceuticals earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Verrica Pharmaceuticals Inc Stock (VRCA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Verrica Pharmaceuticals Inc Stock (VRCA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hayes Christopher G. | CHIEF LEGAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
26,183 |
69,647 |
115,303 |
| Hayes Christopher G. | CHIEF LEGAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
9,530 |
23,444 |
105,773 |
| Goldenberg Gary | Chief Medical Officer |
Aug 26 '24 |
Sale |
2.66 |
9,888 |
26,302 |
97,862 |
| Goldenberg Gary | Chief Medical Officer |
Aug 27 '24 |
Sale |
2.46 |
3,601 |
8,858 |
94,261 |
| Bonaccorso Joe | CHIEF COMMERCIAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
24,709 |
65,726 |
82,107 |
| Bonaccorso Joe | CHIEF COMMERCIAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
8,993 |
22,123 |
73,114 |
| Kohler Terry | CHIEF FINANCIAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
21,820 |
58,041 |
52,596 |
| Kohler Terry | CHIEF FINANCIAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
7,899 |
19,432 |
44,697 |
| White Ted | PRESIDENT AND CEO |
Aug 26 '24 |
Sale |
2.66 |
24,979 |
66,444 |
224,988 |
| White Ted | PRESIDENT AND CEO |
Aug 27 '24 |
Sale |
2.46 |
9,021 |
22,192 |
215,967 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):